M. Habiba et al., EFFECT OF A NEW CYCLICAL SEQUENTIAL POSTMENOPAUSAL HRT ON LIPOPROTEIN, APOPROTEIN AND THROMBOPHILIA PROFILE, European journal of obstetrics, gynecology, and reproductive biology, 62(1), 1995, pp. 89-94
We examined the changes in lipoprotein, apoprotein, and thrombophilia
profile in postmenopausal women using a new cyclical sequential combin
ed HRT regimen. The study medication consisted of two tablets of Hormo
nin (oestriol 0.27 mg, oestrone 1.4 mg and oestradiol 0.6 mg), daily a
nd norethisterone (1 mg) BP (Shire Developments) for the last 12 days
of every 28 day cycle. Serial fasting blood samples were collected at
the beginning of the study and, thereafter, at 3-monthly intervals for
1 year, each patient acting as her own control. Thirty-five healthy p
ostmenopausal women completed 1 year of follow-up and had a complete s
et of fasting blood samples. The lipid profile; total cholesterol, tri
glycerides, HDL, LDL, Apo AI, Apo AII, Apo B and Lp(a), as well as the
coagulation parameters; antithrombin III, factor VII, fibrinogen, pro
tein C and protein S, were measured at each occasion. There was a stat
istically significant drop in total cholesterol and LDL levels. Lp(a)
level dropped after commencing treatment and remained below baseline f
or the rest of the study. The initial increase in Apo AII was not main
tained for the duration of the treatment. The changes in Lp(a) and Apo
AII were not statistically significant. The level of protein S droppe
d significantly throughout the study. The changes in other coagulation
factors were not statistically significant. The effect of this hormon
al combination on the lipid parameters is favourable, and although the
change in protein S is striking, its clinical significance remains un
clear.